ReveraGen BioPharma

Focus: ReveraGen BioPharma is a drug development company focused on therapeutics for rare diseases, particularly Duchenne muscular dystrophy, headquartered in Rockville, MD.

Rare Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About ReveraGen BioPharma

AI assessmentNot Hiring

No open roles listed right now. Follow ReveraGen BioPharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

7 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

VBP15

Healthy

Phase 1

Clinical Trials (1)

NCT02415439A Phase 1 Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects

Phase 1

Help build intelligence for ReveraGen BioPharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline centered on vamorolone across multiple muscular dystrophy indications with Phase 2 programs offering mid-stage clinical development experience
Rare disease focus provides specialized expertise in pediatric neuromuscular disorders and orphan drug pathways
Early-stage company structure offers potential for cross-functional involvement and career acceleration in smaller team environment

Watch Out For

No current active job openings (activeJobCount: 0) indicates company is not actively hiring
Pre-revenue biotech model with unknown funding profile creates uncertainty around runway, cash position, and long-term stability

Generated by Claude from ReveraGen BioPharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Vamorolone 4% suspension for oral dosing

Pediatric Ulcerative Colitis

Phase 1/2

Clinical Trials (1)

NCT04348890Proof of Concept Trial of Vamorolone in Pediatric Ulcerative Colitis

Phase 1/2

Vamorolone 0.25 mg/kg/day

Duchenne Muscular Dystrophy

Phase 2

Vamorolone 0.25 mg/day/day

Duchenne Muscular Dystrophy

Phase 2